Not Yet RecruitingNot Applicable

PK/PD Target Attainment of Ceftriaxone for the Prevention of Early Ventilator-associated Pneumonia in Neurologically Injured Patients

France60 participantsStarted 2026-03-01

Plain-language summary

Critically ill patients admitted for acute brain injury are exposed to many heath-care associated infections such as ventilator associated pneumoniae (VAP). The PROHYVAP study, published in 2024 reported that a single dose of CEFTRIAXONE as an antibiotic prophylaxis could reduce the incidence of early VAP (VAP that occured between day 2 and day 7 of mechanical ventilation). However, patients with acute brain injury also presented frequently augmented renal clearance (ARC), which could affect the pharmacokinetic and pharmacodynamic target attainment (PK/PD) of antibiotic prophylaxis. This study aims to analyse the PK/PD target attainment after one dose of CEFTRIAXONE in critically ill patients with acute brain injury and to describe the effect of ARC on PK/PD target attainment during early VAP.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 18 years or older * Admitted in intensive care unit for acute brain injury, including traumatic brain injury and cerebral vascular disease * Glasgow coma scale inferior to 12 * Orotracheal intubation in first 12 hours of admission * Needed of invasive mechanical ventilation for at least 48 hours Exclusion Criteria: * Acute brain injury related to tumoral or infectious process * Antibiotic therapy administered before acute brain injury for an other pathology * Patients with a risk of multiresistance bacteria contamination (stay in a risk area in the past 3 months, antibiotic therapy with fluoroquinolone or betalctamine in the past 3 months, hospitalization in last month before admission, documented contaminationwith multiresistance bacteria, immunodepression) * Patients with hish risk of death in the first 48 hours * Patients with a beta-lactams reported allergy

What they're measuring

Percentage of patients with PK/PD target attainment

Timeframe: 24 hours

Trial details

NCT IDNCT07450404

SponsorCentral Hospital, Nancy, France

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-09-01

Contact for this trial

Maureen Steib, MD

+33 3 83 85 10 45 m.steib@chru-nancy.fr